[{"orgOrder":0,"company":"C4 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CFT1946","moa":"||BiDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"C4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"C4 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"C4 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||B-raf\/RAF proto-oncogene serine\/threonine-protein kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||B-raf\/RAF proto-oncogene serine\/threonine-protein kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"Erasca","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Naporafenib","moa":"||B-raf\/RAF proto-oncogene serine\/threonine-protein kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Erasca","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Tablet","sponsorNew":"Erasca \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Erasca \/ J.P. Morgan"},{"orgOrder":0,"company":"Erasca","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Naporafenib","moa":"||B-raf\/RAF proto-oncogene serine\/threonine-protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Erasca \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ BofA Securities"},{"orgOrder":0,"company":"Erasca","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Naporafenib","moa":"||B-raf\/RAF proto-oncogene serine\/threonine-protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Erasca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Naporafenib","moa":"||B-raf\/RAF proto-oncogene serine\/threonine-protein kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Erasca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Erasca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Erasca \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"GSK | National Cancer Institute | Susan G. Komen for the Cure","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ GSK | National Cancer Institute | Susan G. Komen for the Cure","highestDevelopmentStatusID":"6","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ GSK | National Cancer Institute | Susan G. Komen for the Cure"},{"orgOrder":0,"company":"Shanghai Chest Hospital","sponsor":"BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Chest Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Chest Hospital \/ BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Chest Hospital \/ BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Genuv","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuv \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genuv \/ Undisclosed"},{"orgOrder":0,"company":"Genuv","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuv \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Undisclosed"},{"orgOrder":0,"company":"Genuv","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Neurology","graph2":"IND Enabling","graph3":"Genuv","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genuv \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Genuv \/ Undisclosed"},{"orgOrder":0,"company":"Cancer Trials Ireland","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Cancer Trials Ireland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cancer Trials Ireland \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Cancer Trials Ireland \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer","highestDevelopmentStatusID":"7","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ Innovative Therapies for Children with Cancer Consortium | IBFM | Fight Kids Cancer"},{"orgOrder":0,"company":"Region Skane","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Region Skane","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Region Skane \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Region Skane \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Pfizer Inc"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Novugen","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"MALAYSIA","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novugen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novugen \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novugen \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"Stand Up To Cancer | Novartis Pharmaceuticals Corporation | Prostate Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ Stand Up To Cancer | Novartis Pharmaceuticals Corporation | Prostate Cancer Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Jonsson Comprehensive Cancer Center \/ Stand Up To Cancer | Novartis Pharmaceuticals Corporation | Prostate Cancer Foundation"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Novartis Pharmaceuticals Corporation | American Cancer Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ Novartis Pharmaceuticals Corporation | American Cancer Society","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Francisco \/ Novartis Pharmaceuticals Corporation | American Cancer Society"},{"orgOrder":0,"company":"Ohio State University Comprehensive Cancer Center","sponsor":"National Comprehensive Cancer Network | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Ohio State University Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University Comprehensive Cancer Center \/ National Comprehensive Cancer Network | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Ohio State University Comprehensive Cancer Center \/ National Comprehensive Cancer Network | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"SCRI Development Innovations, LLC","sponsor":"Bristol Myers Squibb | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"SCRI Development Innovations, LLC","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SCRI Development Innovations, LLC \/ Bristol Myers Squibb | GSK","highestDevelopmentStatusID":"6","companyTruncated":"SCRI Development Innovations, LLC \/ Bristol Myers Squibb | GSK"},{"orgOrder":0,"company":"Cook Children's Health Care System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Cook Children's Health Care System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cook Children's Health Care System \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cook Children's Health Care System \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Children's Oncology Group"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ GSK"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Celldex Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"NYU Langone Health \/ Celldex Therapeutics"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Incyte Corporation"},{"orgOrder":0,"company":"Melanoma Institute Australia","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Melanoma Institute Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Melanoma Institute Australia \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Melanoma Institute Australia \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Peter Hosein, MD","sponsor":"Incyte Corporation | Novartis Pharmaceuticals Corporation | University of Miami Sylvester Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"Peter Hosein, MD","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Peter Hosein, MD \/ Incyte Corporation | Novartis Pharmaceuticals Corporation | University of Miami Sylvester Comprehensive Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Peter Hosein, MD \/ Incyte Corporation | Novartis Pharmaceuticals Corporation | University of Miami Sylvester Comprehensive Cancer Center"},{"orgOrder":0,"company":"TACL Consortium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TACL Consortium","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TACL Consortium \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TACL Consortium \/ Undisclosed"},{"orgOrder":0,"company":"Turning Point Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Repotrectinib","moa":"||NT-3 growth factor receptor | Nerve growth factor receptor Trk-A | ROS1-SDC4 | Neurotrophic tyrosine kinase receptor type 2 | Proto-oncogene tyrosine-protein kinase ROS | CD74-ROS1","graph1":"Oncology","graph2":"Phase II","graph3":"Turning Point Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Turning Point Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Turning Point Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dabrafenib Mesylate","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DCC-3116","moa":"||ULK1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Deciphera Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Trametinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Through the acquisition, Hikma holds the rights of Mekinist-Generic (trametinib dimethyl sulfoxide) tablets from Novugen. It is being indicated for the treatment of BRAF-mutated melanoma.

                          Product Name : Mekinist-Generic

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          April 17, 2025

                          Lead Product(s) : Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Hikma Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Cook Children's Health Care System

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Cook Children's Health Care System

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Trametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Histiocytosis, Langerhans-Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 03, 2024

                          Lead Product(s) : Trametinib

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : ERAS-254 (naporafenib) , an oral Pan-Raf inhibitor is being investigated with trametinib (MEK inhibitor) in patients with NRAS-mutant (NRASm) melanoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 18, 2024

                          Lead Product(s) : Naporafenib,Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Shanghai Chest Hospital

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Shanghai Chest Hospital

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : Trametinib

                          Therapeutic Area : Oncology

                          Study Phase : Phase I/ Phase II

                          Sponsor : BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Trametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 13, 2024

                          Lead Product(s) : Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : BeOne Medicines | Chia Tai Tianqing Pharmaceutical Group | Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The net proceeds will be used to advance the clinical development of ERAS-254 (naporafenib), which is being evaluated in late-stage clinical trials for the treatment of RAS Q61X-mutated melanoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          May 21, 2024

                          Lead Product(s) : Naporafenib,Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : J.P. Morgan

                          Deal Size : $184.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Erasca will use the proceeds to fund R&D of its product candidates, including ERAS-254 (naporafenib) with trametinib for patients with RAS Q61X solid tumors, and other developmental programs.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 27, 2024

                          Lead Product(s) : Naporafenib,Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : BofA Securities

                          Deal Size : $45.0 million

                          Deal Type : Private Placement

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The collaboration will support the clinical development of the pan-RAF inhibitor ERAS-254 (naporafenib) in combination with trametinib for the treatment of patients with RAS Q61X solid tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          February 14, 2024

                          Lead Product(s) : Naporafenib,Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : LXH254 (naporafenib) is a potent and selective pan-RAF inhibitor, it is under phase 3 clinical development in combination with Mekinist (trametinib) for the treatment of NRAS-mutated metastatic melanoma .

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 11, 2023

                          Lead Product(s) : Naporafenib,Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : ERAS-254 (naporafenib) is a potent and selective pan-RAF inhibitor, with a potential first-in-class and best-in-class profile, which is being investigated in combination with MEK inhibitor trametinib (MEKINIST®) in patients with RAS Q61X solid tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 29, 2023

                          Lead Product(s) : Naporafenib,Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          TACL Consortium

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          TACL Consortium

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Trametinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Myelomonocytic, Juvenile.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 09, 2023

                          Lead Product(s) : Trametinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank